Evidence map›Paper›PMID 36015261›Full record

ArticlePharmaceutics2022

Understanding the pH Dependence of Supersaturation State-A Case Study of Telmisartan.

Szabina Kádár, Dóra Csicsák, Petra Tőzsér, Attila Farkas, Tamás Pálla, Arash Mirzahosseini, Blanka Tóth, Gergő Tóth, Béla Fiser, Péter Horváth and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Szabina KádárDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, 3 Műegyetem rkp., 1111 Budapest, Hungary.
Dóra CsicsákDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.
Petra TőzsérDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, 3 Műegyetem rkp., 1111 Budapest, Hungary.
Attila FarkasDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, 3 Műegyetem rkp., 1111 Budapest, Hungary.ORCID 0000-0002-8877-2587
Tamás PállaDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.
Arash MirzahosseiniDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.ORCID 0000-0002-3281-8435
Blanka TóthDepartment of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111 Budapest, Hungary.
Gergő TóthDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.ORCID 0000-0001-5341-319X
Béla FiserInstitute of Chemistry, University of Miskolc, Miskolc-Egyetemváros, 3515 Miskolc, Hungary.ORCID 0000-0003-0603-4626
Péter HorváthDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.ORCID 0000-0001-7149-4173
János MadarászDepartment of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111 Budapest, Hungary.
Alex AvdeefIn-ADME Research, 1732 First Ave., #102, New York, NY 10128, USA.ORCID 0000-0002-3139-5442
Krisztina Takács-NovákDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.
Bálint SinkóPion Inc., 10 Cook Street, Billerica, MA 01821, USA.
Enikő BorbásDepartment of Organic Chemistry and Technology, Budapest University of Technology and Economics, 3 Műegyetem rkp., 1111 Budapest, Hungary.
Gergely VölgyiDepartment of Pharmaceutical Chemistry, Semmelweis University, 9 Hőgyes Endre Street, 1092 Budapest, Hungary.

Funding

Bolyai + New National Excellence Program of the Ministry for Innovation and TechnologyGITDA Governmental Information-Technology Development Agency, HungaryJános Bolyai Research Scholarship of the Hungarian Academy of SciencesMinistry for Innovation and Technology ÚNKP-21-4National Research, Development, and Innovation Fund of Hungary TKP2021-EGA-02
6 · The paper itself

Abstract

Creating supersaturating drug delivery systems to overcome the poor aqueous solubility of active ingredients became a frequent choice for formulation scientists. Supersaturation as a solution phenomenon is, however, still challenging to understand, and therefore many recent publications focus on this topic. This work aimed to investigate and better understand the pH dependence of supersaturation of telmisartan (TEL) at a molecular level and find a connection between the physicochemical properties of the active pharmaceutical ingredient (API) and the ability to form supersaturated solutions of the API. Therefore, the main focus of the work was the pH-dependent thermodynamic and kinetic solubility of the model API, TEL. Based on kinetic solubility results, TEL was observed to form a supersaturated solution only in the pH range 3-8. The experimental thermodynamic solubility-pH profile shows a slight deviation from the theoretical Henderson-Hasselbalch curve, which indicates the presence of zwitterionic aggregates in the solution. Based on p

Indexed as

dimerizationsolubilitysupersaturationtelmisartan

Identifiers

PMID36015261
PMCPMC9412861

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.